The present disclosure provides a method for treating and/or preventing a condition characterized as a nephrotic syndrome, such as but not limited to minimal change disease (MCD) and membranous nephropathy (MN), and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.
